The Folfirinox study will extend the use of oncosil to the most...

The Folfirinox study will extend the use of oncosil to the most common chemo treatment for ca pancreas. At present, it's only gem, so that's a huge chunk of patients excluded from using it based on the approval label (prev CEO and Board error). So, many clinicians will access oncosil in the trial, as it's free. When that's finished, and its an RCT, the client base will extend dramatically and potentially even lead directly to government reimbursement in many countries.

I it would be good to see the current TOTAL number of Oncosil treatments being used, regardless of commercial or research. That might give you some idea of acceptance, and let the market know how things are going.

I think there are several things ready to drop. When they do, I think the market might be ready to reconsider it's position on Oncosil.

But let's see.